Novartis Declares End of Tourmaline Bio Tender Offer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 27 2025
0mins
Should l Buy ?
Source: Globenewswire
Novartis Tender Offer: Novartis announced the expiration of its tender offer to acquire all outstanding shares of Tourmaline Bio, Inc. at a price of $48.00 per share, which ended on October 27, 2025.
Shareholder Response: Approximately 24,030,382 shares, representing about 92.94% of the total shares, were validly tendered and not withdrawn by the expiration date.
Transaction Closure: The acquisition transaction is expected to close on October 28, 2025, following the acceptance of the validly tendered shares.
Forward-Looking Statements: The press release includes forward-looking statements regarding the acquisition and potential future developments, emphasizing the uncertainties and risks involved in the process.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
